Season 2 Episode 4: Two interviews with Joao P. De Aquino, MD and Donovan Maust, MD on the impact of cannabis on OUD treatment, and benzodiazepine discontinuation

Season 2 Episode 4: Two interviews with Joao P. De Aquino, MD and Donovan Maust, MD on the impact of cannabis on OUD treatment, and benzodiazepine discontinuation

This episode of Behind the Evidence offers a deep dive into two significant topics in addiction medicine. First, Dr. Joao P. De Aquino from Yale School of Medicine discusses his study on the impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder (OUD). He reveals that there is no significant association between cannabis use and non-medical opioid use during treatment, challenging the need for mandatory cannabis abstinence policies in opioid treatment programs. Dr.

Aquino emphasises the importance of personalised treatment plans and further research on cannabinoids' role in OUD recovery. Next, Dr. Donovan Maust from the University of Michigan shares his findings on benzodiazepine discontinuation and mortality among long-term users. His study indicates a higher risk of death among those who discontinue benzodiazepines, especially when exposed to opioids. Dr. Maust highlights the need for careful consideration of tapering rates and individual patient contexts in benzodiazepine deprescribing practices.

Both interviews underscore the complexity of substance use treatment and the necessity for evidence-based, nuanced approaches to patient care. Tune in to hear these enlightening discussions and gain a better understanding of current addiction medicine research.